阿帕替尼治疗多线化疗后复发的广泛期小细胞肺癌的效果及对患者生存的影响  

Effect of Apatinib in the treatment of recurrent extensive small cell lung cancer after multi-line chemotherapy and its impact on the survival of patients

作　　者：张海利 董桂兰[1] 刘丽丽[1] 谷雪 吕立丽[1] 胡万宁[1] 王志武[1] HANG Haili;DONG Guilan;LIU Lili;GU Xue;LYU Lili;HU Wanning;WANG Zhiwu(Department of Radiotherapy and Chemotherapy,Tangshan People′s Hospital,Hebei Province,Tangshan 063000,China)

机构地区：[1]河北省唐山市人民医院放化疗科

出　　处：《中国医药导报》2019年第26期100-103,共4页China Medical Herald

基　　金：国家自然科学基金资助项目（81603475）

摘　　要：目的观察阿帕替尼治疗既往接受过多线化疗进展的广泛期小细胞肺癌(SCLC)患者的近期疗效、安全性及其对患者生存的影响。方法回顾性纳入2017年1月~2018年6月于唐山市人民医院放化疗科接受阿帕替尼治疗的SCLC患者62例。用药1个周期(4周)后首次评价疗效,之后每2个周期行一次疗效评价。主要研究终点为无进展生存期(PFS),次要终点为总生存期(OS),采用Kaplan-Meier曲线评估PFS,应用Log-rank对比组间生存差异,根据RECIST 1.1标准评估疗效,根据CTCAE 4.0标准评估不良反应。结果 62例SCLC患者中无CR病例,11例(17.7%)达PR,37例(59.7%)为SD,PD为14例(22.6%)。DCR为48例(77.4%)。中位PFS为3个月(95%CI:1.13~4.87),中位OS为6个月(95%CI:4.27~7.73)。最常见不良反应为继发性高血压(28/62)和手足综合征(34/62),3级不良反应共发生3例。结论阿帕替尼在广泛期SCLC三线或四线治疗中有确切效果,不良反应可耐受。该结果尚需在多中心、大样本量的前瞻性研究中验证。Objective To observe the short-term efficacy, safety and survival of Apatinib in the treatment of patients with extensive small cell lung cancer (SCLC) who had previously undergone multiline chemotherapy. Methods A retrospective study of 62 SCLC patients treated with Apatinib in Department of Radiotherapy and Chemotherapy, Tangshan People′s Hospital from January 2017 to June 2018. The efficacy was evaluated for the first time after 1 cycle (4 weeks). Thereafter, the efficacy was evaluated every two cycles. The primary endpoint was progression-free survival (PFS) and the secondary endpoint was total survival (OS). Kaplan-Meier curve was used to evaluate PFS. Log-rank was used to compare survival differences between groups. The efficacy was evaluated according to RECIST 1.1 criteria, and adverse reactions were evaluated according to CTCAE 4.0 criteria. Results Among the 62 patients with SCLC, there were no CR cases, 11 cases (17.7%) with PR, 37 cases (59.7%) with SD and 14 cases (22.6%) with PD. DCR was 48 cases (77.4%). The median PFS was 3 months (95%CI: 1.13-4.87) and the median OS was 6 months (95%CI: 4.27-7.73). The most common adverse reactions were secondary hypertension (28/62) and hand-foot syndrome (34/62), and grade 3 adverse reactions occurred in 3 cases. Conclusion Apatinib has a definite effect in the third or fourth line treatment of extensive SCLC, and the adverse reactions are tolerable. The results need to be validated in a multi-center, large-sample prospective study.

关 键 词：阿帕替尼 小细胞肺癌 生存分析 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]